BC Innovations | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

ASH presentations on immune reprogramming point to new targets and mechanisms that control macrophage and T cell phenotype switching, and highlight the phenomenon's translational relevance in diseases beyond solid tumors. Strategies to convert immunosuppressive macrophage...
BC Innovations | Mar 13, 2019
Distillery Therapeutics

IKKβ inhibition for tendinopathy

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Patient sample, cell culture and mouse studies suggest inhibiting IKKβ could help treat tendinopathy. In tendon tissues samples from patients with rotator cuff disease, levels of IKKβ protein were higher...
BC Innovations | Dec 4, 2018
Distillery Therapeutics


INDICATION: Inflammation In vitro , cell culture and mouse studies identified an OGG1 inhibitor that could help treat pulmonary inflammation. Screening of a small molecule library via an in vitro activity assay, followed by optimization of...
BioCentury | Nov 17, 2018
Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
BC Innovations | Nov 13, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Mouse studies suggest inhibiting MCP-1 or its receptor CCR2 could help treat arthritis. In a mouse model of anti-collagen antibody-induced arthritis, systemic MCP-1 knockout or a neutralizing antibody against CCR2 decreased disease severity...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinal detachment Mouse studies suggest inhibiting TRPV4 or its downstream mediator MCP-1 could help treat retinal detachment. In a mouse model of retinal detachment, systemic or Müller glia- and astrocyte-specific TRPV4 knockout, a tool...
BC Innovations | Sep 10, 2018
Distillery Therapeutics


INDICATION: Encephalopathy Patient sample and mouse studies suggest inhibiting the JAK/STAT1 pathway, the interaction between MCP-1 and CCR2, or phagocyte activation could help treat Rasmussen encephalitis. In postmortem brain samples from patients, levels of phosphorylated...
BC Innovations | Aug 3, 2018
Targets & Mechanisms

Oxitope’s oxidation play

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The...
BC Innovations | Nov 15, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinopathy of prematurity Patient sample and mouse studies suggest inhibiting mast cell degranulation, TPSB2 or MCP-1-CCR2 signaling could help treat retinopathy of prematurity (ROP). In plasma samples from preterm neonatal infants who developed ROP,...
BC Innovations | Oct 24, 2017
Distillery Techniques


TECHNOLOGY: Plasma markers Serum levels of IL-6 and MCP-1 could help predict the risk of neurologic adverse events in patients receiving lymphodepletion chemotherapy and CAR T cell therapy. In 133 patients with CD19 -positive B...
Items per page:
1 - 10 of 85